

BMS-8

Chemical Properties


CAS No. : 1675201-90-7

Formula: C₂₇H₂₈BrNO₃

Molecular Weight: 494.42

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC ₅₀ : 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
Targets(IC ₅₀)	PD-1/PD-L1
In vitro	BMS-8 demonstrates a more stable binding affinity for one PD-L1 monomer compared to another, with its ability to induce PD-L1 dimerization further enhanced by non-polar interactions involving Ile54, Tyr56, Met115, Ala121, and Tyr123 on each monomer, in addition to the involvement of water-mediated bridges at ALys124[2].

Solubility Information

Solubility	DMSO: 15.31 mg/mL (30.97 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0226 mL	10.1129 mL	20.2257 mL
5 mM	0.4045 mL	2.0226 mL	4.0451 mL
10 mM	0.2023 mL	1.0113 mL	2.0226 mL
50 mM	0.0405 mL	0.2023 mL	0.4045 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Régis JM, Grob JJ. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. *Eur J Cancer*. 2017 Oct;84:44-54.
- Danfeng Shi, et al. Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. *Front Chem*. 2019 Nov 12;7:764.
- Zhang BC, Wang C, Li WH, Li DY. Clinical outcome of drug-eluting versus bare-metal stents in patients with calcified coronary lesions: a meta-analysis. *Intern Med J*. 2015 Feb;45(2):203-11.
- Barenes H, Empis G, Quang TD, Sengkhamyong K, Phasavath P, Harimanana A, Sambany EM, Koffi PN. Breast-milk substitutes: a new old-threat for breastfeeding policy in developing countries. A case study in a traditionally high breastfeeding country. *PLoS One*. 2012;7(2):e30634.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481